Epigenomics AG Receives Allowance for Key Patent in Europe

BERLIN and SEATTLE, July 29, 2008 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt Prime Standard:ECX), a molecular diagnostics company focusing on the development and commercialization of products for cancer detection based on DNA methylation, today announced that it received a Rule 71(3) notification stating that the European Patent Office intends to grant a patent for Epigenomics’ Septin 9 biomarker. This notification is equivalent to a “Notice of Allowance” by the United States Patent and Trademark Office. Patent application EP 1721992, titled “Methods and nucleic acids for analyses of cellular proliferative disorders,” claims very broadly methods, substances and kits for the methylation analysis of Epigenomics’ Septin 9 biomarker. The patent application is also pending in the USA, Japan and 15 other countries outside of Europe.

MORE ON THIS TOPIC